NRX-1074 in Early Course Schizophrenia

Summary

This study seeks to examine the effectiveness of NRX-1074 in the treatment of negative symptoms and cognition in schizophrenia compared to other agents at the glycine site which have demonstrated inconsistent results for negative symptoms. In addition to testing efficacy, we will examine the time course of response of symptoms as well as any effects on memory consolidation.

Timeline

Start

—

Primary completion

2020-08

Completion

—

Outcome

Outcome not reported

Stopped: “The study was withdrawn by the sponsor.”

Drugs

Indications